This is illustrated by 13.5% of RA patients from our outpatient clinic using non-TNF inhibitor bDMARDs in 2013, whereas the figures for our PsA patients were 1.3% in 2013 and 3.5% in 2017 [7]. This evidence concerns the gene TNF and rheumatoid arthritis.